14.89
+0.275(+1.88%)
Currency In USD
| Previous Close | 14.61 |
| Open | 14.73 |
| Day High | 15.46 |
| Day Low | 14.68 |
| 52-Week High | 18.38 |
| 52-Week Low | 8.24 |
| Volume | 1.04M |
| Average Volume | 804,908 |
| Market Cap | 986.8M |
| PE | -4.18 |
| EPS | -3.56 |
| Moving Average 50 Days | 14.02 |
| Moving Average 200 Days | 13.17 |
| Change | 0.28 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $807.21 as of August 24, 2025 at a share price of $14.885. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $1,235.27 as of August 24, 2025 at a share price of $14.885.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
GlobeNewswire Inc.
Aug 04, 2025 8:05 PM GMT
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
GlobeNewswire Inc.
Jun 30, 2025 3:17 PM GMT
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systol
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reducti